1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Aladdin Healthcare Technologies SE

Aladdin Healthcare Technologies SE

ALDNF
Aladdin Healthcare Technologies SEUS flagOther OTC
0.01
USD
- -
- -
160,415.00Market Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
Revenue per Share
- -
- -
- -
0.02
- -
- -
Basic EPS, GAAP
- -
-0.01
- -
-0.49
-0.26
-0.11
Free Cash Flow per Basic Share
- -
-0.01
-0.04
-0.31
-0.15
-0.06
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
0.03
0.02
-0.06
0.46
0.18
0.07
Tangible Book Value per Share
0.03
0.02
-0.17
-0.08
-0.15
-0.24
Basic Weighted Avg Shares
12
12
12
11
11
11
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
-1,637.67
- -
- -
Depreciation Expense
- -
- -
- -
- -
2
- -
Net Income, GAAP
- -
- -
- -
-5
-3
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-3,089.77
- -
- -
Working Capital
- -
- -
-1
- -
-1
-3
LT Debt
- -
- -
- -
- -
1
- -
Total Equity
- -
- -
-1
1
-2
-3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-39.33
- -
- -
-84.41
-85.91

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-212.98%
53.12%
Free Cash Flow
- -
1,116.76%
-60.74%
Net Income, GAAP
- -
2,416.94%
-58.77%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
-0.26
2020
- -
- -
- -
- -
-0.11
2021
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Wade Menpes-Smith
Full Time Employees
3
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
Unter den Linden 10 Berlin Germany 10117
IPO Date
Mar 24, 2021
Website
aladdinid.com
Similar Companies
TrivarX Limited (TRI.AX)
Lift & Co. Corp. (LFCOF)
SCWorx Corp. (WORX)
Change Healthcare Inc. (CHNG)
CompuGroup Medical SE & Co. KGaA (0MSD.L)
Vitalhub Corp. (VHI.TO)
Business
Aladdin Healthcare Technologies SE develops artificial intelligence-driven software solutions for healthcare data management, diagnostics, and drug discovery targeting age-related diseases. Founded in 2014 and headquartered in Berlin, Germany, at Unter den Linden 10, the company operates through its subsidiary Aladdin Healthcare Technologies Ltd and focuses on blockchain technology for secure storage and management of health information; it serves global markets with emphasis on Europe, China, and India. Core products and services include an Artificial Intelligence assisted Drug Discovery platform identifying small molecule compounds for conditions such as Alzheimer's disease, Parkinson's disease, and SARS-CoV-2; PharmaKG, a biomedical knowledge graph for advanced data analytics; a Disease Diagnosis and Risk Assessment Platform leveraging machine learning and predictive analytics; and AI-based diagnostics encompassing blood testing, advanced image processing, and early detection of chronic diseases. Recent developments encompass regulatory approval for listing on the OTCQB market in the United States in late 2021, discovery of 20 optimized compounds for COVID-19 treatment using its AI drug discovery platform, signing of a memorandum of understanding with an Indian partner for validation and distribution of diagnostics and drug discovery applications, accumulation of 2.3 million anonymized electronic medical records on its platforms, and leadership transitions including the appointment of Wade Menpes-Smith as CEO.